Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Eekman, Danielle A ^a   Vis, Marijn ^a   Bultink, Irene E M ^a   Derikx, Harm J G M ^a   Dijkmans, Ben A C ^a,b   Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PAMIDRONIC ACID; PREDNISONE; RISEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; GASTROINTESTINAL DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; RETROSPECTIVE STUDY; SPINE; TIME; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL DISEASES; HIP JOINT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 68349124977     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-86     Document Type: Article

References (16)

1. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. M Vis IE Bultink BA Dijkmans WF Lems, Osteoporos Int 2005 16 1432 1435 10.1007/s00198-005-1862-z 15883662 (Pubitemid 41532096)
2. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. A Cranney P Tugwell J Adachi B Weaver N Zytaruk A Papaioannou, Endocr Rev 2002 23 517 523 10.1210/er.2001-3002 12202466 (Pubitemid 34925645)
3. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. A Cranney G Wells A Willan L Griffith N Zytaruk V Robinson, Endocr Rev 2002 23 508 516 10.1210/er.2001-2002 12202465 (Pubitemid 34925644)
4. Quality of life in patients with osteoporosis. P Lips NM van Schoor, Osteoporos Int 2005 16 447 455 10.1007/s00198-004-1762-7 15609073
5. Mortality after all major types of osteoporotic fracture in men and women: an observational study. JR Center TV Nguyen D Schneider PN Sambrook JA Eisman, Lancet 1999 353 878 882 10.1016/S0140-6736(98)09075-8 10093980 (Pubitemid 29126875)
6. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. DC Bauer D Black K Ensrud D Thompson M Hochberg M Nevitt, Arch Intern Med 2000 160 517 525 10.1001/archinte.160.4.517 10695692
7. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi, Osteoporos Int 2000 11 83 91 10.1007/s001980050010 10663363 (Pubitemid 30099515)
8. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. PD Miller, Clin Ther 2005 27 361 376 10.1016/j.clinthera.2005.04.005 15922811 (Pubitemid 40732645)
9. Compliance with treatment regimens in chronic asymptomatic diseases. NH Miller, Am J Med 1997 102 43 49 10.1016/S0002-9343(97)00467-1 9217586 (Pubitemid 27147947)
10. Pharmacokinetics of alendronate. AG Porras SD Holland BJ Gertz, Clin Pharmacokinet 1999 36 315 328 10.2165/00003088-199936050-00002 10384857 (Pubitemid 29261508)
11. Uncertain future of trials in osteoporosis. JA Kanis A Oden O Johnell F Caulin H Bone JM Alexandre, Osteoporos Int 2002 13 443 449 10.1007/s001980200052 12107656 (Pubitemid 34742201)
12. Surrogates for fracture endpoints in clinical trials. S Khosla, J Bone Miner Res 2003 18 1146 1149 10.1359/jbmr.2003.18.6.1146 12817773 (Pubitemid 37294958)
13. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. D Marshall O Johnell H Wedel, BMJ 1996 312 1254 1259 8634613
14. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. MC Hochberg PD Ross D Black SR Cummings HK Genant MC Nevitt, Arthritis Rheum 1999 42 1246 1254 10.1002/1529-0131(199906)42:6<1246::AID-ANR223.0.CO;2-U 10366118
15. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley, N Engl J Med 2007 356 1809 1822 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
16. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. PD Delmas S Adami C Strugala JA Stakkestad JY Reginster D Felsenberg, Arthritis Rheum 2006 54 1838 1846 10.1002/art.21918 16729277 (Pubitemid 43877933)